AKT1 and neoplasm: Additionally, this compound interferes with the mitogen-activated protein kinase (MAPK) pathway by inhibiting extracellular signal-regulated kinase (ERK) phosphorylation and suppresses the vascular endothelial growth factor 2 (VEGFR2)-regulated Ak strain, transforming (AKT)/mammalian target of rapamycin (mTOR)/P70S6K signaling in both endothelial cells [48] and tumor models [49] (Figure 4).